Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma… http://t.co/r6YGrTMYqQ
#negativeresult for @GSK's Relvar, no sig. difference in improvement compared to control for #asthma sufferers http://t.co/xZpN7gkbce
#negativeresult for @GSK's Relvar, no sig. difference in improvement compared to control for #asthma sufferers http://t.co/xZpN7gkbce
#negativeresult for @GSK's Relvar, no sig. difference in improvement compared to control for #asthma sufferers http://t.co/xZpN7gkbce
.@GSK publishes #negativeresult on vilanterol in @JNRBM - http://t.co/xZpN7gkbce #asthma #AllTrials
.@GSK publishes #negativeresult on vilanterol in @JNRBM - http://t.co/xZpN7gkbce #asthma #AllTrials
.@GSK publishes #negativeresult on vilanterol in @JNRBM - http://t.co/xZpN7gkbce #asthma #AllTrials
.@GSK publishes #negativeresult on vilanterol in @JNRBM - http://t.co/xZpN7gkbce #asthma #AllTrials
.@GSK publishes #negativeresult on vilanterol in @JNRBM - http://t.co/xZpN7gkbce #asthma #AllTrials
Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in... http://t.co/ZJtakOhINn